10-Q: Charlotte's Web Q1 2026 Results Show Revenue Decline, BAT Deal Nears

Charlotte's Web Holdings, Inc. reported a 9.0% decrease in revenue for the first quarter of 2026 compared to the prior year, alongside a significant increase in the fair value loss of financial instruments, while awaiting shareholder approval for a major transaction with British American Tobacco.

Summary

• Revenue for the first quarter ended March 31, 2026, decreased by 9.0% to $11.16 million compared to $12.26 million in the same period of 2025.
• Product revenue saw a 9.1% decline, attributed to a strategic shift towards a more margin-accretive distributor model for the retail business.
• Cost of goods sold decreased by 1.3% to $5.96 million, partly offset by increased variable operating costs and startup costs for in-house manufacturing.
• Gross profit decreased by 16.5% to $5.20 million, with gross margin falling to 46.6% from 50.8% year-over-year.
• Selling, general, and administrative expenses decreased by 17.7% to $9.53 million, primarily due to cost-cutting measures in personnel.
• The company reported a net loss of $13.11 million for the quarter, an increase from a net loss of $6.21 million in Q1 2025.
• A significant factor in the increased net loss was a substantial change in the fair value of financial instruments, resulting in a loss of $8.87 million, primarily from the revaluation of the debt conversion option and investment in DeFloria.
• Net cash used in operating activities was $2.78 million, a slight increase from $2.77 million in the prior year's quarter.
• The company announced a transaction with British American Tobacco (BAT) on March 30, 2026, involving the conversion of BAT's convertible debenture and a $10 million equity investment, subject to shareholder and TSX approval.
• If completed, the BAT transaction would eliminate approximately $65 million in debt and simplify the company's capital structure.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant revenue decline, widening net loss, and substantial fair value losses on financial instruments, despite positive strategic developments and a potential debt-reducing transaction.

Positives

• Selling, general, and administrative expenses were reduced by 17.7% due to cost-cutting measures, including workforce adjustments.
• The company is strategically shifting its retail business to a more margin-accretive distributor model.
• The company is progressing with its strategic transformation, diversifying product offerings beyond CBD into functional mushrooms, minor cannabinoids, and hemp-derived THC.
• The FDA has allowed DeFloria, a collaboration involving Charlotte's Web, to proceed with Phase 2 clinical trials for a treatment for symptoms of autism spectrum disorder (ASD).
• Charlotte's Web is planning to participate in a pilot program with the Center for Medicare and Medicaid Innovation (CMMI) to provide CBD products for senior oncology patients.
• The proposed transaction with BAT, if completed, would eliminate significant debt and simplify the company's capital structure.

Negatives

• Total revenue decreased by 9.0% to $11.16 million in Q1 2026 compared to Q1 2025.
• Gross profit decreased by 16.5% to $5.20 million, and gross margin declined to 46.6% from 50.8%.
• The net loss widened significantly to $13.11 million from $6.21 million in the prior year's quarter.
• A substantial loss of $8.87 million was recorded due to changes in the fair value of financial instruments, primarily related to the debt conversion option.
• Cash used in operating activities remained a significant outflow at $2.78 million.
• Inventories decreased slightly to $17.18 million from $18.02 million, but remain a substantial asset.
• The company's total shareholders' deficit increased to $15.04 million from $2.04 million.

Risks

• Regulatory changes in various states continue to impact the company's ability to sell certain products as currently formulated or packaged, requiring ongoing assessment of business and financial impacts.
• The company faces risks related to the fair value measurement of its investment in DeFloria and its convertible debt derivatives, which involve significant subjectivity and judgment using unobservable inputs.
• The successful completion of the proposed transaction with BAT is subject to conditions, including TSX and shareholder approval.
• The company's ability to fund operations long-term depends on future operating performance, revenue growth, and expense management, which are subject to general economic conditions, industry regulatory changes, and other factors beyond its control.
• The company has a significant amount of convertible debenture debt outstanding, which carries conversion features and interest rate adjustments based on federal regulation of CBD.

Future Outlook

Management believes that the Company's existing cash and cash equivalents, and short-term investments will provide sufficient liquidity to fund operations and planned capital expenditures for the next 12 months. The Company expects a continued cost containment strategy in overall selling, general, and administrative expenses in 2026. The Company's ability to fund its operations for the longer term will depend on future operating performance, particularly revenue growth and expense management, which can be affected by general economic conditions, industry regulatory changes, and other factors beyond the Company's control.

Management Comments

• Charlotte's Web's mission is to 'Unearth the Science of Nature to Revolutionize Wellness,' and is evolving its wellness offerings both to strengthen the Company's core leadership in CBD, and extend beyond CBD to include a broader range of botanical-based wellness solutions, including minor cannabinoids.
• The Company's strategic transformation includes product diversification beyond CBD into functional mushroom, minor cannabinoid, and hemp-derived THC categories.
• The Company completed full internalization of Brightside gummy production, providing multi-million-unit manufacturing capacity with improved quality control and supply chain resilience.
• The Company will offer a set of products to address oncology patient needs in 2026 through a secure online healthcare portal.
• Upon completion of the Transaction with BAT, approximately $65 million of total debt will be eliminated from the Company's balance sheet, interest on the debenture will stop accruing, and liquidity will increase for near-term operations. The Company would operate with no long-term debt and with a simplified equity structure.

Industry Context

StockSavvy.ai notes that Charlotte's Web's strategic pivot towards product diversification into functional mushrooms, minor cannabinoids, and hemp-derived THC aligns with broader industry trends seeking to expand the wellness market beyond traditional CBD. The company's focus on clinical trials and potential participation in Medicare/Medicaid pilot programs indicates an effort to legitimize and integrate cannabinoid-based wellness into mainstream healthcare, a significant development in the evolving regulatory landscape.

Comparison to Industry Standards

• Charlotte's Web's gross margin of 46.6% for Q1 2026 is below the typical range for established consumer packaged goods companies, which often aim for higher margins through scale and brand strength. However, within the specialized CBD/hemp wellness sector, this margin may be competitive, especially considering the company's efforts to optimize its supply chain and shift to a distributor model.
• The company's net loss of $13.11 million in Q1 2026 highlights the ongoing profitability challenges faced by many companies in the nascent and highly regulated cannabis and hemp-derived product industries. Competitors in this space also frequently report net losses as they invest heavily in R&D, marketing, and navigating complex regulatory environments.
• The significant increase in the fair value loss of financial instruments ($8.87 million in Q1 2026 vs. $0.13 million in Q1 2025) is a notable item. This volatility is not uncommon for companies with complex financial structures, including convertible debt and embedded derivatives, but it significantly impacts reported earnings and is a key area for investors to monitor, especially when compared to peers with simpler capital structures.

Legal Proceedings

• From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. Management believes that as of March 31, 2026, there is no litigation pending that could have, individually and in the aggregate, a material adverse effect on the Company's financial position, results of operations or cash flows.
• The Company is not a party to any material pending legal proceedings, other than ordinary routine litigation incidental to the business.

Related Party Transactions

• The Company issued a secured promissory note in November 2020, loaning $1,000 to one of the Stanley Brothers, with a maturity date extended to November 13, 2029. No additional interest will accrue through the payment date, and the note has been fully reserved for.
• The Company entered into a Master Services Agreement with DeFloria, receiving $75 in revenue and incurring $75 in cost of goods sold for services provided in Q1 2026 and Q1 2025.
• The Company has an accounts receivable balance due from DeFloria of $1,546 as of March 31, 2026.
• The Company loaned $750 to DeFloria on July 15, 2025, with a balance of $805 including accrued interest as of March 31, 2026.
• The Company entered into a consulting agreement with Jared Stanley, a former executive and current Board member, for a bi-weekly fee of $6.

Stakeholder Impact

• Shareholders: The proposed transaction with BAT, if approved, could significantly alter the company's capital structure by eliminating debt and issuing new shares, potentially impacting future earnings per share and ownership percentages.
• Creditors: The elimination of approximately $65 million in debt through the BAT transaction would be a significant positive for creditors.
• Employees: Cost-cutting measures, including workforce adjustments, have been implemented, impacting employee numbers and potentially morale.
• Suppliers: The shift to a distributor model for retail business may indirectly affect supplier relationships and terms.
• Customers: The company is diversifying its product line and exploring new channels like a healthcare portal for oncology patients, potentially impacting product availability and access.

Next Steps

• Shareholders will be asked to approve the transaction with BAT at an annual general and special meeting of shareholders to be held on or about May 28, 2026.
• The company plans to offer a set of products to address oncology patient needs in 2026 through a secure online healthcare portal as part of the CMMI pilot program.
• The company will continue to assess the business and financial impacts of new state regulations on product formulation, labeling, and costs.
• The company will continue to execute its cost containment strategy in overall selling, general, and administrative expenses.

Key Dates

Recommendation

While the proposed transaction with BAT offers a path to debt reduction and a simplified capital structure, the company's core business continues to face revenue declines and widening losses. The significant increase in fair value losses on financial instruments adds considerable uncertainty. The 'hold' recommendation reflects a cautious approach, awaiting clearer signs of operational improvement and successful integration of strategic initiatives, alongside the outcome of the critical BAT transaction approval.

Keywords

Charlotte's Web, CBD, Hemp Extract, Form 10-Q, Quarterly Report, Financial Results, British American Tobacco, BAT, Convertible Debenture, Revenue, Net Loss, Fair Value, Financial Instruments, DeFloria, AJNA BioSciences, FDA, Clinical Trials, CMMI, Oncology, Securities and Exchange Commission